Announcement by Sumitomo Pharma America, Inc. (SMPA) of the First Patient Receiving a Transplant in the Phase 1/2 Study of an iPSC-Derived Retinal Sheet Therapy for Retinitis Pigmentosa in the U.S.

2026.08.13

Research and Development

Development of the Regenerative Medicine Product “AMCHEPRY®” Receives the 10th Japan Bioindustry Award

2026.07.15

Research and Development

Announcement by Sumitomo Pharma America, Inc. (SMPA) Regarding the U.S. Orphan Drug Designation for an Allogeneic iPS cell-derived Retinal Sheet (3-dimensional retina) as a Treatment for Retinitis Pigmentosa

2026.03.24

Research and Development

Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY®” in Japan

2026.03.06

Research and Development